Neurology:24例LGMDR12成人患者两年随访的前瞻性自然史研究:定量MRI和临床结果评估

2022-06-30 Naomi MedSci原创

肢体-Girdle肌营养不良症常染色体隐性遗传性12型(LGMDR12)一种罕见的遗传性肌营养不良症。Biodex®等长肌力测力仪可捕捉LGMDR12患者一年中肌肉力量损失,并作为未来临床预后指标。

肢体-Girdle肌营养不良症常染色体隐性遗传性12型(LGMDR12)是一种罕见的遗传性肌营养不良症,目前缺乏改善预后措施。近日,一项发表在Neurology上的研究评估了跟踪疾病进展的定量MRI和临床结果指标,以确定哪些测试在未来的临床试验中可能有用,以评估潜在的治疗方法。

研究人员前瞻性地测量了所有参与者在基线以及1年和2年后的以下结果:6分钟步行距离(6MWD)、10米步行试验(10MWT)、医学研究委员会(MRC)总分、Biodex®等长肌力测力仪、血清肌酸激酶(CK)和大腿6点Dixon MRI。

  • 研究包括24名经基因确认的成人LGMDR12患者和24名年龄和性别匹配的健康对照。
  • 接受中期大腿肌肉脂肪置换的患者(质子密度脂肪分数(PDFF)为20-70%)在一年后评估的14个大腿肌肉中,有8个已经显示出PDFF显著增加。
  • 标准化反应平均数(SRM)显示该组中6块肌肉在2年内对PDFF的变化有较高的反应能力。然而,在早期(<20%)或终末期(>70%)肌肉脂肪置换的患者中,PDFF在两年的随访中没有显著增加。
  • Biodex®等长肌力测力仪显示,所有患者的右、左腿肌肌力(分别为-6.2 Nm,p<0.002和-4.6Nm,p<0.009)和右股四头肌(-9 Nm,p=0.044)的肌力显著下降,而6MWD、10MWT和MRCsum评分即使在两年后也没有检测到肌肉功能/力量的显著下降。在基线时,大腿全长PDFF与临床结果指标之间存在中等强度的相关性。

在选定的LGMDR12患者中,即使在一年的随访后,大腿肌肉PDFF成像也是一种跟踪进行性肌肉脂肪替代的敏感结果指标,并与临床结果指标相关。Biodex®等长肌力测力仪可以可靠地捕捉LGMDR12患者一年中肌肉力量的损失,并应作为未来临床试验的结果指标。

文献来源:De Wel B, Huysmans L, Peeters R, et al. Prospective Natural History Study in 24 Adult Patients With LGMDR12 Over 2 Years' Follow-up: Quantitative MRI and Clinical Outcome Measures [published online ahead of print, 2022 May 16]. Neurology. 2022;10.1212/WNL.0000000000200708. doi:10.1212/WNL.0000000000200708

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1950427, encodeId=fd52195042eca, content=<a href='/topic/show?id=dfd4e8626e1' target=_blank style='color:#2F92EE;'>#结果评估#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78626, encryptionId=dfd4e8626e1, topicName=结果评估)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Tue May 09 07:15:20 CST 2023, time=2023-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085360, encodeId=fc77208536062, content=<a href='/topic/show?id=3fc2459e9ce' target=_blank style='color:#2F92EE;'>#定量MRI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45979, encryptionId=3fc2459e9ce, topicName=定量MRI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8dba135, createdName=xuyong523, createdTime=Thu Oct 13 02:15:20 CST 2022, time=2022-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898900, encodeId=bfe9189890079, content=<a href='/topic/show?id=729322969b9' target=_blank style='color:#2F92EE;'>#临床结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22969, encryptionId=729322969b9, topicName=临床结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Sun Feb 05 02:15:20 CST 2023, time=2023-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991686, encodeId=6ca319916868c, content=<a href='/topic/show?id=b8b11141ed8' target=_blank style='color:#2F92EE;'>#MDR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11417, encryptionId=b8b11141ed8, topicName=MDR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b27406, createdName=syscxl, createdTime=Wed Oct 12 13:15:20 CST 2022, time=2022-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997399, encodeId=9ba5199e39904, content=<a href='/topic/show?id=67ec86244b1' target=_blank style='color:#2F92EE;'>#自然史#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86244, encryptionId=67ec86244b1, topicName=自然史)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ced3193, createdName=freve, createdTime=Mon Jan 30 17:15:20 CST 2023, time=2023-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006570, encodeId=c16820065e0a3, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Mon Sep 26 10:15:20 CST 2022, time=2022-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001846, encodeId=eb0d2001846ea, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Sep 29 22:15:20 CST 2022, time=2022-09-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1950427, encodeId=fd52195042eca, content=<a href='/topic/show?id=dfd4e8626e1' target=_blank style='color:#2F92EE;'>#结果评估#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78626, encryptionId=dfd4e8626e1, topicName=结果评估)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Tue May 09 07:15:20 CST 2023, time=2023-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085360, encodeId=fc77208536062, content=<a href='/topic/show?id=3fc2459e9ce' target=_blank style='color:#2F92EE;'>#定量MRI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45979, encryptionId=3fc2459e9ce, topicName=定量MRI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8dba135, createdName=xuyong523, createdTime=Thu Oct 13 02:15:20 CST 2022, time=2022-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898900, encodeId=bfe9189890079, content=<a href='/topic/show?id=729322969b9' target=_blank style='color:#2F92EE;'>#临床结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22969, encryptionId=729322969b9, topicName=临床结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Sun Feb 05 02:15:20 CST 2023, time=2023-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991686, encodeId=6ca319916868c, content=<a href='/topic/show?id=b8b11141ed8' target=_blank style='color:#2F92EE;'>#MDR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11417, encryptionId=b8b11141ed8, topicName=MDR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b27406, createdName=syscxl, createdTime=Wed Oct 12 13:15:20 CST 2022, time=2022-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997399, encodeId=9ba5199e39904, content=<a href='/topic/show?id=67ec86244b1' target=_blank style='color:#2F92EE;'>#自然史#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86244, encryptionId=67ec86244b1, topicName=自然史)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ced3193, createdName=freve, createdTime=Mon Jan 30 17:15:20 CST 2023, time=2023-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006570, encodeId=c16820065e0a3, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Mon Sep 26 10:15:20 CST 2022, time=2022-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001846, encodeId=eb0d2001846ea, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Sep 29 22:15:20 CST 2022, time=2022-09-29, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1950427, encodeId=fd52195042eca, content=<a href='/topic/show?id=dfd4e8626e1' target=_blank style='color:#2F92EE;'>#结果评估#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78626, encryptionId=dfd4e8626e1, topicName=结果评估)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Tue May 09 07:15:20 CST 2023, time=2023-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085360, encodeId=fc77208536062, content=<a href='/topic/show?id=3fc2459e9ce' target=_blank style='color:#2F92EE;'>#定量MRI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45979, encryptionId=3fc2459e9ce, topicName=定量MRI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8dba135, createdName=xuyong523, createdTime=Thu Oct 13 02:15:20 CST 2022, time=2022-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898900, encodeId=bfe9189890079, content=<a href='/topic/show?id=729322969b9' target=_blank style='color:#2F92EE;'>#临床结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22969, encryptionId=729322969b9, topicName=临床结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Sun Feb 05 02:15:20 CST 2023, time=2023-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991686, encodeId=6ca319916868c, content=<a href='/topic/show?id=b8b11141ed8' target=_blank style='color:#2F92EE;'>#MDR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11417, encryptionId=b8b11141ed8, topicName=MDR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b27406, createdName=syscxl, createdTime=Wed Oct 12 13:15:20 CST 2022, time=2022-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997399, encodeId=9ba5199e39904, content=<a href='/topic/show?id=67ec86244b1' target=_blank style='color:#2F92EE;'>#自然史#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86244, encryptionId=67ec86244b1, topicName=自然史)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ced3193, createdName=freve, createdTime=Mon Jan 30 17:15:20 CST 2023, time=2023-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006570, encodeId=c16820065e0a3, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Mon Sep 26 10:15:20 CST 2022, time=2022-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001846, encodeId=eb0d2001846ea, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Sep 29 22:15:20 CST 2022, time=2022-09-29, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1950427, encodeId=fd52195042eca, content=<a href='/topic/show?id=dfd4e8626e1' target=_blank style='color:#2F92EE;'>#结果评估#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78626, encryptionId=dfd4e8626e1, topicName=结果评估)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Tue May 09 07:15:20 CST 2023, time=2023-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085360, encodeId=fc77208536062, content=<a href='/topic/show?id=3fc2459e9ce' target=_blank style='color:#2F92EE;'>#定量MRI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45979, encryptionId=3fc2459e9ce, topicName=定量MRI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8dba135, createdName=xuyong523, createdTime=Thu Oct 13 02:15:20 CST 2022, time=2022-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898900, encodeId=bfe9189890079, content=<a href='/topic/show?id=729322969b9' target=_blank style='color:#2F92EE;'>#临床结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22969, encryptionId=729322969b9, topicName=临床结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Sun Feb 05 02:15:20 CST 2023, time=2023-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991686, encodeId=6ca319916868c, content=<a href='/topic/show?id=b8b11141ed8' target=_blank style='color:#2F92EE;'>#MDR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11417, encryptionId=b8b11141ed8, topicName=MDR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b27406, createdName=syscxl, createdTime=Wed Oct 12 13:15:20 CST 2022, time=2022-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997399, encodeId=9ba5199e39904, content=<a href='/topic/show?id=67ec86244b1' target=_blank style='color:#2F92EE;'>#自然史#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86244, encryptionId=67ec86244b1, topicName=自然史)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ced3193, createdName=freve, createdTime=Mon Jan 30 17:15:20 CST 2023, time=2023-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006570, encodeId=c16820065e0a3, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Mon Sep 26 10:15:20 CST 2022, time=2022-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001846, encodeId=eb0d2001846ea, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Sep 29 22:15:20 CST 2022, time=2022-09-29, status=1, ipAttribution=)]
    2022-10-12 syscxl
  5. [GetPortalCommentsPageByObjectIdResponse(id=1950427, encodeId=fd52195042eca, content=<a href='/topic/show?id=dfd4e8626e1' target=_blank style='color:#2F92EE;'>#结果评估#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78626, encryptionId=dfd4e8626e1, topicName=结果评估)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Tue May 09 07:15:20 CST 2023, time=2023-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085360, encodeId=fc77208536062, content=<a href='/topic/show?id=3fc2459e9ce' target=_blank style='color:#2F92EE;'>#定量MRI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45979, encryptionId=3fc2459e9ce, topicName=定量MRI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8dba135, createdName=xuyong523, createdTime=Thu Oct 13 02:15:20 CST 2022, time=2022-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898900, encodeId=bfe9189890079, content=<a href='/topic/show?id=729322969b9' target=_blank style='color:#2F92EE;'>#临床结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22969, encryptionId=729322969b9, topicName=临床结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Sun Feb 05 02:15:20 CST 2023, time=2023-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991686, encodeId=6ca319916868c, content=<a href='/topic/show?id=b8b11141ed8' target=_blank style='color:#2F92EE;'>#MDR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11417, encryptionId=b8b11141ed8, topicName=MDR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b27406, createdName=syscxl, createdTime=Wed Oct 12 13:15:20 CST 2022, time=2022-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997399, encodeId=9ba5199e39904, content=<a href='/topic/show?id=67ec86244b1' target=_blank style='color:#2F92EE;'>#自然史#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86244, encryptionId=67ec86244b1, topicName=自然史)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ced3193, createdName=freve, createdTime=Mon Jan 30 17:15:20 CST 2023, time=2023-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006570, encodeId=c16820065e0a3, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Mon Sep 26 10:15:20 CST 2022, time=2022-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001846, encodeId=eb0d2001846ea, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Sep 29 22:15:20 CST 2022, time=2022-09-29, status=1, ipAttribution=)]
    2023-01-30 freve
  6. [GetPortalCommentsPageByObjectIdResponse(id=1950427, encodeId=fd52195042eca, content=<a href='/topic/show?id=dfd4e8626e1' target=_blank style='color:#2F92EE;'>#结果评估#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78626, encryptionId=dfd4e8626e1, topicName=结果评估)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Tue May 09 07:15:20 CST 2023, time=2023-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085360, encodeId=fc77208536062, content=<a href='/topic/show?id=3fc2459e9ce' target=_blank style='color:#2F92EE;'>#定量MRI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45979, encryptionId=3fc2459e9ce, topicName=定量MRI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8dba135, createdName=xuyong523, createdTime=Thu Oct 13 02:15:20 CST 2022, time=2022-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898900, encodeId=bfe9189890079, content=<a href='/topic/show?id=729322969b9' target=_blank style='color:#2F92EE;'>#临床结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22969, encryptionId=729322969b9, topicName=临床结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Sun Feb 05 02:15:20 CST 2023, time=2023-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991686, encodeId=6ca319916868c, content=<a href='/topic/show?id=b8b11141ed8' target=_blank style='color:#2F92EE;'>#MDR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11417, encryptionId=b8b11141ed8, topicName=MDR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b27406, createdName=syscxl, createdTime=Wed Oct 12 13:15:20 CST 2022, time=2022-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997399, encodeId=9ba5199e39904, content=<a href='/topic/show?id=67ec86244b1' target=_blank style='color:#2F92EE;'>#自然史#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86244, encryptionId=67ec86244b1, topicName=自然史)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ced3193, createdName=freve, createdTime=Mon Jan 30 17:15:20 CST 2023, time=2023-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006570, encodeId=c16820065e0a3, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Mon Sep 26 10:15:20 CST 2022, time=2022-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001846, encodeId=eb0d2001846ea, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Sep 29 22:15:20 CST 2022, time=2022-09-29, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1950427, encodeId=fd52195042eca, content=<a href='/topic/show?id=dfd4e8626e1' target=_blank style='color:#2F92EE;'>#结果评估#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78626, encryptionId=dfd4e8626e1, topicName=结果评估)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Tue May 09 07:15:20 CST 2023, time=2023-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085360, encodeId=fc77208536062, content=<a href='/topic/show?id=3fc2459e9ce' target=_blank style='color:#2F92EE;'>#定量MRI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45979, encryptionId=3fc2459e9ce, topicName=定量MRI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8dba135, createdName=xuyong523, createdTime=Thu Oct 13 02:15:20 CST 2022, time=2022-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898900, encodeId=bfe9189890079, content=<a href='/topic/show?id=729322969b9' target=_blank style='color:#2F92EE;'>#临床结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22969, encryptionId=729322969b9, topicName=临床结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Sun Feb 05 02:15:20 CST 2023, time=2023-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991686, encodeId=6ca319916868c, content=<a href='/topic/show?id=b8b11141ed8' target=_blank style='color:#2F92EE;'>#MDR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11417, encryptionId=b8b11141ed8, topicName=MDR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b27406, createdName=syscxl, createdTime=Wed Oct 12 13:15:20 CST 2022, time=2022-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997399, encodeId=9ba5199e39904, content=<a href='/topic/show?id=67ec86244b1' target=_blank style='color:#2F92EE;'>#自然史#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86244, encryptionId=67ec86244b1, topicName=自然史)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ced3193, createdName=freve, createdTime=Mon Jan 30 17:15:20 CST 2023, time=2023-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006570, encodeId=c16820065e0a3, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Mon Sep 26 10:15:20 CST 2022, time=2022-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001846, encodeId=eb0d2001846ea, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Sep 29 22:15:20 CST 2022, time=2022-09-29, status=1, ipAttribution=)]
    2022-09-29 yinhl1978

相关资讯

从4大类指标,手把手教你制定类风关复查计划!

众所周知,类风湿关节炎是属于慢性风湿病,需要长期治疗。复查指标作为患者管理的一部分非常重要,哪些指标需要复查?需要多久复查?一文讲清楚。

DCR: 直肠癌中淋巴细胞与单核细胞和血小板与淋巴细胞比率可以对患者预后进行预测

新辅助化疗是指在实施局部治疗方法(如手术或放疗)前所做的全身化疗,目的是使肿块缩小、及早杀灭看不见的转移细胞,以利于后续的手术、放疗等治疗。对于早期肿瘤患者通常可以通过局部治疗方案治愈。

Neurology:接受血管内治疗(EVT)的急性脑卒中(AIS)患者中,活动性癌症患者在90天功能预后更差!

近日,有研究人员试图比较接受血管内治疗(EVT)治疗的急性脑卒中(AIS)患者和活动性癌症患者的临床、影像学和安全性结果。研究发现,在接受EVT治疗的AIS患者中,活动性癌症患者在90天功能预后更差。

Neurology:ENCT随机对照试验:脑动脉瘤血管内治疗后发生的医源性脑梗死与术后认知、临床随访指标差异相关

近日,研究人员对接受颅内动脉瘤血管内修复治疗的患者进行了ENCT随机对照试验。研究发现医源性脑梗死与不同量表评估下的术后(1-4天)、30天结局的细微差异有关,早期的功能障碍与后期差异相关。

Neurology:儿童癫痫手术后的连接特征和认知轨迹

儿童颞叶癫痫手术后的神经认知结果是不同的。近日,研究报道了以弥漫性连接为特征的连接,这让人联想到发育不成熟的网络,与手术前认知较差和手术后认知改善有关。这为了解颞叶癫痫术后认知与预后变化提供潜在手段。

JNNP:综合临床运动评分作为帕金森病综合敏感预后指标

到目前为止,尽管进行了多项神经保护治疗试验,但没有一项被明确证明能改变帕金森病(PD)的进展。他们的失败,至少在一定程度上,被归咎于使用了不敏感的终点和结果指标。普渡钉板测试是一种针对不同疾病和年龄组

拓展阅读

JNER:肌营养不良患者神经肌肉受试者手臂功能辅助系统:一项随机对照研究

肌营养不良症(MDs)是指一组以进行性加重的肌无力和支配运动的肌肉变性为特征的遗传性疾病群。肌营养不良症包括先天性肌营养不良症。部分肌营养不良症会导致运动受损甚至瘫痪。临床上主要表现为不同程度和分布的

JACC:干细胞治疗肌营养不良的实验研究

尽管心肌病已经成为Duchenne肌营养不良(DMD)的主要死因,但是目前尚无有效治疗手段。本研究的目的旨在利用DMD患者特异性人诱导多能干细胞(hiPSC)来源的心肌细胞来探究可能的药物治疗手段。

MYO-101基因疗法治疗肢带肌营养不良症的积极结果

Sarepta制药公司本周三透露,2型肢带型肌营养不良症(LGMD2E)基因治疗候选药物MYO-101在3名患者的I / IIa期研究中展现了积极的阳性结果。

Cell Stem Cell:科学家利用畸胎瘤成功衍生出肌肉干细胞

近日,来自明尼苏达大学医学院的科学家们通过研究开发了一种新方法,能通过名为畸胎瘤的良性肿瘤为肌营养不良症的小鼠机体再生骨骼肌细胞,相关研究刊登于国际杂志Cell Stem Cell上。

Sci Adv:CRISPR再入新领域!肌营养不良症的基因治疗或可成真!

以CRISPR/Cas9为基础的基因编辑技术在艾滋病、血液病、肿瘤等多种遗传性疾病的基因治疗领域中展现出极大的应用前景。杜氏肌营养不良是一种X染色体隐性遗传疾病,医学界尚无有效疗法。近日,有研究人员指出,CRISPR/Cas9可用于杜氏肌营养不良症的基因治疗,打破该病无药可治无法可医的局面。